| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.075 | 0.1 |
| mRNA | Bexarotene | FIMM | pan-cancer | AAC | -0.23 | 0.1 |
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | -0.11 | 0.1 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.048 | 0.1 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | 0.055 | 0.1 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | -0.056 | 0.1 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.049 | 0.1 |
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | 0.046 | 0.1 |
| mRNA | momelotinib | CTRPv2 | pan-cancer | AAC | -0.05 | 0.1 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.053 | 0.1 |